NCT04908215View on ClinicalTrials.gov

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

April 3, 2023

Study Completion Date

April 19, 2023

Conditions
Epidermolysis Bullosa SimplexEpidermolysis Bullosa, JunctionalEpidermolysis Bullosa DystrophicaKindler Syndrome
Interventions
DRUG

INM-755 (cannabinol) cream

topical cream containing cannabinol for dermal application

DRUG

Vehicle Cream

topical cream base for dermal application containing no active agent

Trial Locations (7)

16121

Andreas Syggros Hospital of Cutaneous Venereal Diseases, Athens

20122

Fondazione IRCCS Ca Granda. Ospedale Maggiore Policlinico, Milan

31059

CHU Toulouse - Hopital Larrey, Toulouse

75010

Hopital Saint Louis APHP Paris, Paris

79104

Universitaetsklinikum Freiburg, Freiburg im Breisgau

6423930

Tel Aviv Sourasky Medical Center, Tel Aviv

00167

Instituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome

Sponsors
All Listed Sponsors
lead

InMed Pharmaceuticals Inc.

INDUSTRY